(Investorideas.com Newswire) A popular platform for great investment ideas, including cannabis stocks, Tilray Brands, Inc. Issues a news and trading alert for.Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX:TLRY) has already been extremely volatile in early trading, with the day’s range being $7.59 – $9.27. Shares in the sector were up yesterday and continued to rise in early trade, but now they are all looking in the red. Tilray is currently trading at 7.69 -0.18(-2.29%).
Tilray released a statement today praising President Donald Trump’s actions to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act – a defining inflection point that represents a fundamental shift in U.S. drug policy, opening up significant opportunities for medical cannabis clinical research, patient access, and industry standardization. This action represents the most consequential federal cannabis policy development in decades, accelerating the emergence of a regulated, science-driven medical cannabis framework in the United States.
Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, said:
“Today is a critical moment for the United States. With President Trump’s action to reschedule cannabis, federal policy is finally aligning with science, medicine, and most importantly, patient needs. It’s about the people: patients fighting cancer, seniors managing chronic pain, veterans dealing with PTSD, and children with epilepsy whose families have long been seeking safe, effective alternatives. For decades, they have turned to medical cannabis. Today, the system begins to catch up to them. Redefinition has the potential to accelerate clinical research, broaden access, and raise the quality, consistency, and safety standards that establish medical cannabis as a legitimate pillar of modern health care.”
“At Tilray, we have built a global platform for precisely this moment. We are among the world’s largest cannabis producers with more than 7 million square feet of cultivation capacity and a recognized global leader in pharmaceutical-grade cannabis production, clinical research, product innovation and patient care. Through Tilray Medical, we have served hundreds of thousands of patients in more than 20 countries in some of the world’s most tightly regulated markets. This is how healthcare evolves. Tilray stands ready to partner with regulators and health care providers to responsibly expand access to medical cannabis and help shape the future of this industry in the United States.
Research Cannabis Stocks at Investorideas.com
https://www.investorideas.com/Marijuana-Stocks/stocks_list.asp
Sign up for free trading and stock news alerts at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of news, articles and equity research sourced from third parties and also creates original content including videos, interviews and articles. Original content created by Investidea is protected by copyright laws in addition to syndication rights. Our site does not make recommendations for the purchase or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investments involve risk and possible loss of investment. The site currently offers compensation for news publishing and distribution, social media and marketing, content creation, and more. Contact each company directly regarding content and press release questions. More disclosure information: https://www.investorideas.com/About/Disclaimer.asp
This article is a third party guest post published content and not the content of Investorideas.com. Learn more about posting your articles at http://www.investorideas.com/Advertise/
Global investors must follow the regulations of each country. Please read the Privacy Policy of Investorideas.com: https://www.investorideas.com/About/Private_Policy.asp
